SCHEMBL3638282

SCHEMBL3638282

CC(C)(C)OC(=O)N1CCC(NC(=O)c2ccc(-n3cccn3)cc2)CC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 4/20 0.69
HDAC4 P56524 2/20 0.55
POLB P06746 1/20 0.52
LMNA P02545 2/20 0.49
THRB P10828 1/20 0.49
RIPK2 O43353 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
PIK3CD O00329 1/20 0.48
KDM4E B2RXH2 1/20 0.47
PKM P14618 1/20 0.47
KMT2A Q03164 1/20 0.47
USP30 Q70CQ3 2/20 0.47
PARP1 P09874 1/20 0.47
PRKAB2 O43741 1/20 0.47
PRKAG1 P54619 1/20 0.47
PRKAA2 P54646 1/20 0.47
PRKAA1 Q13131 1/20 0.47
PRKAG3 Q9UGI9 1/20 0.47
PRKAG2 Q9UGJ0 1/20 0.47
PRKAB1 Q9Y478 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3668182 0.94 GPR119 (0.64) GPR119HDAC4HDAC6PIK3CDUSP30
SCHEMBL4946478 0.94 GPR119 (0.64) GPR119HDAC4HDAC6PIK3CDUSP30
SCHEMBL4942925 0.83 HDAC4 (0.52) GPR119HDAC4POLBLMNATHRB
SCHEMBL15507101 0.82 GPR119 (1.00) GPR119
SCHEMBL4603719 0.81 HDAC4 (0.63) HDAC4POLBHDAC6KDM4EPKM
SCHEMBL28975873 0.81 HDAC4 (0.60) GPR119HDAC4POLBHDAC6KDM4E
SCHEMBL13199301 0.81 KDM4E (0.68) GPR119HDAC4POLBLMNATHRB
SCHEMBL3636580 0.81 GPR119 (0.83) GPR119USP30
SCHEMBL3723766 0.81 HDAC4 (0.54) GPR119HDAC4POLBLMNATHRB
SCHEMBL8366262 0.80 KMT2A (0.70) GPR119HDAC4POLBLMNAHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155719-A1 AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS Wyeth LLC (US) 2010-02-24 EP disclosed
WO-2008147945-A1 AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS WYETH (US) 2008-12-04 WO disclosed
US-20080293771-A1 AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS WYETH (US) 2008-11-27 US disclosed
US-20080293771-A1 AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS WYETH (US) 2008-11-27 US disclosed
US-20080293771-A1 AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS WYETH (US) 2008-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293771-A1 AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS HRH4, HRH3, HRH2 GPR119 655/4885HDAC4 652/4885POLB 3600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.